Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents.
A novel in vitro dissolution test for drug-eluting stents (DES) based on the compendial flow-through cell was developed. The model contains an additional compartment simulating the vessel wall enabling the examination of drug release and distribution. The compartment consists of alginate hydrogel containing a central aperture forming the lumen for stent placement and media flow. The method was tested utilizing stents coated with hydrophilic (fluorescein sodium) and hydrophobic (triamterene) fluorescent model substances as well as the cytostatic drug doxorubicin hydrochloride and compared to standard dissolution methods. The results show the suitability of the developed method to observe drug release and distribution. The determination of model substance content in the compartments media, hydrogel and stent yielded differing distribution patterns for the model compounds and enabled the observation of redistribution processes. The dissolution profiles differed from the results of compendial dissolution testing. Besides lower endpoints and slower rises of media concentrations due to distribution into the hydrogel, the release rates from the stent coatings were altered. These findings emphasize the necessity to adapt dissolution testing for DES to the unique conditions influencing delivery to the vessel wall to learn more about local distribution and to anticipate the in vivo performance of DES.
Institute of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, University of Greifswald, Friedrich-Ludwig-Jahn-Strasse 17, 17487 Greifswald, Germany.
Anne
A
Neubert
Katrin
K
Sternberg
Stefan
S
Nagel
Claus
C
Harder
Klaus-Peter
KP
Schmitz
Heyo K
HK
Kroemer
Werner
W
Weitschies
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry; D020099:Coated Materials, Biocompatible / Q000737:chemistry; D003331:Coronary Vessels / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D054855:Drug-Eluting Stents; D006801:Humans; D008954:Models, Biological; D012995:Solubility
D000903:Antibiotics, Antineoplastic; D020099:Coated Materials, Biocompatible; D004317:Doxorubicin